Question 1

What is the difference between semaglutide and tirzepatide?

Accepted Answer

Semaglutide (Ozempic, Wegovy) is a single-pathway GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist, activating two incretin pathways at once. Head-to-head trials (SURPASS-2) showed tirzepatide produced greater HbA1c reduction and weight loss on average. Both are approved for type 2 diabetes and chronic weight management, and both share the same injection schedule (once weekly). Always discuss which is right for you with a qualified clinician.

Question 2

How do GLP-1 medications like Ozempic and Mounjaro work?

Accepted Answer

GLP-1 receptor agonists mimic a natural gut hormone released after eating. They stimulate insulin secretion only when blood sugar is high (glucose-dependent), suppress glucagon, slow gastric emptying, and act on hypothalamic satiety centers to reduce appetite. The combined effect is lower blood glucose and meaningful appetite and food-noise reduction.

Question 3

What is the minimum effective dose philosophy for GLP-1 therapy?

Accepted Answer

The minimum effective dose philosophy prioritizes the smallest dose that produces your desired clinical response over the maximum label dose. The rationale: incretin receptors can downregulate with aggressive escalation, side effects scale with dose, and long-term sustainability often hinges on tolerability. Many clinicians now titrate patients more slowly than the label and hold at a lower "sweet spot" dose if results are adequate. Your clinician should personalize this.

Question 4

Why do GLP-1 medications cause nausea, and how can I reduce it?

Accepted Answer

GLP-1 slows gastric emptying and signals satiety centers — both of which can produce nausea, especially during dose escalation or after overeating. Strategies that help: titrate slowly, eat smaller portions, avoid very high-fat meals, stay hydrated, and stop eating at the first sign of fullness. Persistent severe nausea warrants talking to your provider — dose adjustment is often appropriate.

Question 5

Will I lose muscle on a GLP-1 medication?

Accepted Answer

Any rapid weight loss carries a risk of muscle loss — and GLP-1 medications are no exception. Clinical trials suggest 20-40% of total weight lost can be lean mass if no protective steps are taken. The two best defenses are adequate protein intake (research supports 1.6-2.2 g per kg of body weight per day) and resistance training at least 2-3 times per week. These two levers preserve most lean mass even in meaningful caloric deficits.

Question 6

What labs should I monitor on GLP-1 therapy?

Accepted Answer

Commonly monitored labs include: HbA1c and fasting glucose (glycemic response), lipid panel (often improves), comprehensive metabolic panel (kidney and liver function), CBC, and in select patients amylase/lipase if pancreatitis symptoms arise. Baseline thyroid function and, for patients with risk factors, an assessment of MTC history should also be considered. Frequency depends on your clinician but every 3-6 months is common during titration.

Question 7

Do GLP-1 agonists cause pancreatitis?

Accepted Answer

GLP-1 agonists carry a labeled warning for acute pancreatitis. Large cohort studies and meta-analyses have not shown a consistent population-level signal, but individual cases do occur. Red flags warranting immediate medical evaluation include severe, persistent upper-abdominal pain (often radiating to the back), nausea, and vomiting. People with a history of pancreatitis should discuss risk carefully with their clinician.

Question 8

Who should avoid GLP-1 receptor agonists?

Accepted Answer

Absolute contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Caution is warranted with severe gastroparesis, prior pancreatitis, active gallbladder disease, pregnancy, and certain bariatric surgery histories. Always disclose your full medical history to your prescribing clinician.

Question 9

What is 'food noise' and why does it go away on GLP-1 medications?

Accepted Answer

Food noise is the intrusive, constant thinking about food — planning meals, thinking about snacks, and mental preoccupation with eating. Many patients report a dramatic reduction in food noise on GLP-1 therapy, likely because these drugs act directly on hypothalamic and reward-circuit neurons that drive eating motivation. The effect is often more psychologically significant than the physical satiety.

Question 10

Will I regain the weight if I stop the medication?

Accepted Answer

Trials such as STEP-4 show that most patients who discontinue GLP-1 therapy regain roughly two-thirds of lost weight within a year. This is because GLP-1 medications treat the underlying appetite regulation — they do not cure obesity. Think of them the way you would blood pressure medication: effective while taken. Sustainable lifestyle changes (protein, strength training, sleep, stress management) improve maintenance even if the medication is eventually stopped.

Question 11

Where and how should I inject GLP-1 medications?

Accepted Answer

The three approved subcutaneous injection sites are the abdomen (at least 2 inches from the navel), the front of the thigh, and the back of the upper arm. Rotate sites weekly to minimize irritation and nodules. Pinch the skin, insert at 90 degrees with an autoinjector, and hold for the required count your device specifies. Always use fresh, properly stored pens — semaglutide and tirzepatide must be refrigerated before first use.

Question 12

Can I drink alcohol on GLP-1 medications?

Accepted Answer

There is no absolute prohibition, but many patients notice changes in how alcohol affects them: slower metabolism, more pronounced nausea, and in some cases dramatically reduced desire to drink. Preliminary research suggests GLP-1 agonists reduce reward-seeking behavior broadly, including alcohol cravings. If you drink, do so in moderation and be mindful of interactions with nausea and dehydration.

Question 13

Are compounded GLP-1 medications safe?

Accepted Answer

Compounded semaglutide and tirzepatide filled the supply gap during the official shortage period. With the shortage now resolved in the US, the FDA has restricted most large-scale compounding. Risks include inconsistent potency, contamination, and mislabeling. If using a compounded product, verify it is from a state-licensed 503A pharmacy and that the active ingredient is the approved base, not the salt form (acetate).

Question 14

Is it safe to stack peptides with GLP-1 therapy?

Accepted Answer

Stacking means combining two or more peptides for complementary effects — for example, a GLP-1 agonist plus a muscle-preserving peptide. There is very limited clinical evidence for most stacks, and drug interactions, additive side effects, and injection fatigue are real concerns. Any stacking should be discussed with a clinician who understands both medications, and bloodwork should be monitored more closely.

Question 15

Why am I losing hair on a GLP-1 medication?

Accepted Answer

Hair shedding on GLP-1 therapy is almost always telogen effluvium — a stress response triggered by rapid weight loss and nutrient shifts, not a direct drug effect. It typically peaks 2-4 months into meaningful weight loss and self-resolves within 6-9 months. Protective strategies: protein sufficiency, adequate calories, iron/ferritin/vitamin D monitoring, and slower dose titration if possible.

Question 16

What is retatrutide and when will it be available?

Accepted Answer

Retatrutide is Eli Lilly's investigational triple agonist of GLP-1, GIP, and glucagon receptors. Phase 2 results (NEJM 2023) showed up to 24.2% average weight loss at 48 weeks — the largest effect size ever reported in a published peptide obesity trial. It is currently in Phase 3 trials (TRIUMPH program). FDA approval timing depends on trial completion and regulatory review and has not been publicly confirmed.

Question 17

How do GLP-1 medications interact with women's hormones?

Accepted Answer

GLP-1 therapy can affect menstrual cycles, fertility, and hormonal contraception effectiveness. Rapid weight loss can restore ovulation in women with PCOS, so effective contraception is important if pregnancy is not desired. The label specifically warns that oral contraceptive absorption may be reduced due to slowed gastric emptying — an alternative or backup method is often recommended, especially during escalation.

Question 18

I've plateaued on GLP-1. What should I do?

Accepted Answer

Plateaus are normal and expected. Before increasing the dose, review the fundamentals: protein intake, resistance training, sleep, hydration, and caloric drift. If those are solid, talk to your clinician about dose optimization, switching agents (e.g., semaglutide → tirzepatide), or adding behavioral strategies. Avoid rapid dose increases purely to break a plateau — that is the scenario most associated with downregulation and side-effect escalation.

Frequently Asked Questions

Still Have Questions?